PLIANT THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Pliant Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Pliant Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$57.8M, a 39.2% decline year-over-year.
  • Pliant Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$202M, a 29.9% decline year-over-year.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$161M, a 30.8% decline from 2022.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$123M, a 26.8% decline from 2021.
  • Pliant Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$97.3M, a 134% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$202M -$57.8M -$16.3M -39.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$185M -$55.9M -$14.7M -35.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$171M -$47M -$9.41M -25.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$161M -$41.1M -$6.05M -17.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$155M -$41.5M -$10.9M -35.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$144M -$41.2M -$11.6M -39.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$133M -$37.5M -$9.45M -33.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$123M -$35.1M -$10.5M -42.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$113M -$30.6M -$3.57M -13.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$109M -$29.5M -$6.72M -29.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$103M -$28.1M -$5.24M -22.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$97.3M -$24.5M -$5.5M -28.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$91.8M -$27M -$10.5M -63.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$81.2M -$22.8M -$5.83M -34.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$75.4M -$22.9M -$33.9M -307% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$41.5M -$19M -$61.2M -145% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $19.7M -$16.5M -$3.28M -24.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $22.9M -$17M -$1.48M -9.53% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 $24.4M $11M +$25.1M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$631K $42.2M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$13.3M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$15.5M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$14M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.